Biocon Secures 10-Year Pertuzumab Supply Contract in Brazil

Long-Term Supply Agreement Strengthens Brazil Presence: Biocon has secured a 10-year supply agreement for Pertuzumab in Brazil through a partnership with Bahiafarma and Bionovis. The agreement is part of Brazil’s Productive Development Partnership (PDP) programme, supporting supply to the country's public healthcare system. The consortium has received 100% allocation under the 10-year programme, providing access to a significant portion of Brazil’s public-market demand for Pertuzumab. Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer, making the agreement strategically important for Biocon’s oncology portfolio. Biocon is expected to benefit through milestone payments and a share of revenues generated from the Brazil opportunity over the contract period. Strategic Significance for Biocon Biologics Growth: The agreement strengthens Biocon’s presence in the global biosimilars and oncology market. Brazil represents an important emerging market for affordable complex biologic medicines, while the partnership also supports local technology transfer and manufacturing capabilities. A 10-year arrangement provides potentially greater revenue visibility compared with shorter-term supply contracts. The partnership builds on Biocon’s broader strategy of expanding access to high-quality biosimilars across international markets. Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security.